Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,444.25
(
0.00%
)
US TECH 100
28,590.00
(
0.01%
)
Dow Jones
49,693.20
(
0.00%
)
Brent Oil
102.62
(
-1.04%
)
Bitcoin
79,346.00
(
0.08%
)
News Focus
News Focus
Post# of 257557
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122977
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: geneman post# 161921

Sunday, 06/02/2013 3:19:22 PM

Sunday, June 02, 2013 3:19:22 PM

Post# of 257557

Amgen tested T-Vec against subcutaneous GM-CSF, not against any of the current active agents.

Well, GM-CSF is not exactly inactive; in fact, a phase-2 study presented at ASCO showed that Leukine + Yervoy worked better than Yervoy alone (http://www.healio.com/hematology-oncology/highlights-from-asco-2013/gm-csf-plus-ipilimumab-extended-os-in-metastatic-melanoma ).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today